<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00583531</url>
  </required_header>
  <id_info>
    <org_study_id>06-007216</org_study_id>
    <nct_id>NCT00583531</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of AST-120 in the Treatment of Antibiotic-Refractory Pouchitis</brief_title>
  <official_title>A Pilot Study of the Safety and Efficacy of AST-120 in the Treatment of Antibiotic-Refractory Pouchitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ocera Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ocera Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label pilot study in which all patients will receive AST-120 for 4 weeks.
      Patients will discontinue antibiotics at study entry. They may continue other previously
      prescribed treatments (e.g., probiotics and/or nutritional agents) at the discretion of the
      study doctor. The purpose of the study is to assess whether the investigational medication
      AST-120 will be a safe and effective treatment for the symptoms of pouchitis, a chronic
      inflammatory condition, in patients whose symptoms have not responded well to antibiotics. An
      initial group of 10 patients will be enrolled. If there are no serious side effects
      associated with the study drug and at least 3 of the 10 patients respond, a second group of
      10 patients may be enrolled. Patients will have clinic visits at the start of the study and
      at week 4. Patients will be checked by phone on a weekly basis for symptom response,
      compliance and development of side effects. Endoscopies will be performed at the start of the
      study and at week 4 or early termination.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with acute pouchitis are typically treated with metronidazole or ciprofloxacin for
      10-14 days. Most patients with pouchitis respond to these or other antibiotics. Patients who
      experience frequent relapses and those with chronic pouchitis will require long term
      maintenance antibiotics. Probiotics may be considered as an alternate to chronic antibiotic
      therapy for maintenance of remission in chronic antibiotic-dependent pouchitis. In practice,
      we would institute maintenance therapy for patients who relapse at least 3 times within one
      year, or within 1 month of discontinuation of antibiotics. Among patients receiving
      maintenance antibiotics who develop loss of clinical benefit after prolonged treatment,
      rotation of three or four antibiotics in 1-week intervals may be beneficial. Patients who do
      not improve with single antibiotics may respond to combination therapy with two antibiotics.
      If not, they can be treated with topical or oral budesonide. Other options include topical
      mesalamine (enemas or suppositories), oral sulfasalazine or mesalamine, other topical or oral
      steroids, and possibly oral bismuth, azathioprine, 6-mercaptopurine or infliximab. However,
      there is little evidence base for these therapies in the literature, and many of these
      therapies are expensive and/or potentially toxic. A therapy that does not suppress the immune
      system, and that has little or no toxicity would be attractive for patients with
      antibiotic-refractory pouchitis.

      AST-120 is manufactured by Kureha Corporation, Japan. The agent was approved in Japan in 1991
      for the treatment of patients with chronic kidney disease(CKD). It is comprised of highly
      adsorptive, porous, spherical carbon particles and is packaged in 2 g sachets for oral
      administration designed for the treatment of gastrointestinal diseases. AST-120 consists of
      black microspheres approximately 0.2-0.4 mm in diameter with high adsorption ability and
      large surface area. Composed mainly of carbon (approximately 96%), the clinical utility of
      AST-120 is thought to reside in its ability to adsorb small molecular weight toxins,
      inflammatory mediators, and harmful bile acid products from the gastrointestinal tract,
      preventing local toxicity and their systemic absorption. AST-120 has a selective adsorption
      profile for certain acidic and basic organic compounds, and has a significantly lower
      adsorptive capacity than activated charcoal for digestive enzymes.

      In this study, patients with active pouchitis after ileal pouch-anal anastomosis (IPAA) for
      Ulcerative Colitis with primary symptoms such as increased stool frequency and abdominal
      pain, and refractory to antibiotics (do not respond to antibiotic therapy for a minimum of 14
      days) will be enrolled. Patients must have active pouchitis confirmed by endoscopy and biopsy
      within 4 weeks of study entry. The diagnosis of active pouchitis will be defined by a PDAI
      score &gt;7 points, with a combined assessment of symptoms, endoscopy and histology.

      Eligible patients will receive AST-120 sachets at 2g three times daily (TID) to be taken
      between meals at 10:00 am, 3:00 pm and immediately before going to bed for 4 complete weeks.
      AST-120 is a tasteless, odorless, oral preparation. To take the product, patients will tear
      open the sachets, drop the contents directly on their tongue and wash it down with 8 ounces
      of water. Patients will be evaluated at baseline and week 4 or early termination by the study
      physician, including endoscopies with histology and routine laboratory tests. Patients will
      be checked on a weekly basis by the study coordinator by phone for symptom response,
      compliance, and development of adverse events. Quality of Life Assessments (Cleveland Global
      Quality of Life and Short Inflammatory Bowel Questionnaire) will be conducted at baseline and
      week 4 or early termination. A patient is defined as having completed study treatment if
      he/she has received investigational product and is followed for safety through the last
      on-site visit of the 4 week treatment course.

      Any co-prescribed medicine must be given at least 30 minutes before AST-120 administration.
      The following drugs for pouchitis can be co-prescribed/maintained during AST-120 treatment
      and their utilization will be recorded as secondary endpoints:

        -  Antidiarrheal therapy with loperamide (Imodium)

        -  Nutritional agents and Probiotics at the same dose as previously prescribed, if the dose
           has been stable for 2 weeks at study entry.

      Antibiotics must be stopped by the time of entry into the study. However, antibiotics
      prescribed to treat infection other than pouchitis will be allowed and recorded.

      The need to prescribe any of the following drugs during the study will constitute treatment
      failure:

        -  Oral or topical corticosteroids

        -  Oral or topical 5-ASA

        -  Nutritional agents (SCFA enemas or suppositories, glutamine, dietary fibers)

        -  Probiotics

        -  Narcotic-based antidiarrheal agents

      In addition patients will be considered to have failed treatment if they have a PDAI score
      improvement of &lt; or = 2 points at the end of the trial. Patients will be discontinued from
      the study if they become pregnant or if warranted by treatment-emergent safety concerns or
      if, in the opinion of the investigator, it is in the patient's best interest to discontinue
      the study.

      A first cohort of 10 patients will be treated; based on outcome (efficacy and safety: no
      significant Adverse Event (AE) associated with study drug and at least 3/10 patients
      responding) a second cohort of 10 patients may be enrolled.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Lack of enrollment
  </why_stopped>
  <start_date>March 2007</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response as defined by a decrease in the Pouchitis Diseases Activity Index (PDAI) score of at least 3 points</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety: Any adverse events (AEs) deemed possibly, probably, or definitely related to treatment with investigational product during 4 weeks of treatment</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Remission, as defined as a PDAI score of less than 7 points</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction of PDAI clinical symptom subscore of at least 1 point</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction of PDAI endoscopic subscore of at least 1 point</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction of PDAI histology subscore of at least 1 point</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for rescue medication/quantity of antidiarrheal medication used during the last week of the trail compared to usage in the week prior to study entry</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life as measured by the Cleveland Global QoL instrument and Short Inflammatory Bowel Disease Questionnaire (SIBDQ)</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Significant change in clinical laboratory tests</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Worsening GI symptoms (diarrhea, abdominal pain, urgency or bleeding) or new GI and extra-GI symptoms (e.g., headache, nausea, vomiting, constipation)</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Significant change in physical examination, including vital signs (blood pressure, heart rate, respiration rate and temperature)</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Pouchitis</condition>
  <arm_group>
    <arm_group_label>I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Active treatment with AST-120</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AST-120</intervention_name>
    <description>Oral, 2 grams TID in sachets for 4 weeks</description>
    <arm_group_label>I</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with active pouchitis (defined as having a PDAI score &gt; 7) after IPAA for UC,
             despite at least 14 days of antibiotic therapy. Active pouchitis must be confirmed by
             endoscopy and histology within 4 weeks of study entry

          -  Able to give informed consent

          -  Able and willing to comply with all study procedures

        Exclusion Criteria:

          -  Patients previously treated with infliximab or any investigational immunosuppressant/
             immunomodulator for pouchitis

          -  Patients undergoing chemotherapy for the treatment of cancer

          -  Presence of other inflammatory diseases of the pouch: Crohn's disease, Cuffitis,
             active specific infection of the pouch: (e.g., CMV, C. difficile)

          -  History of non-inflammatory disease of the pouch: decreased pouch compliance,
             irritable pouch syndrome, afferent or efferent limb obstruction, stricture of pouch

          -  Ileal pouch patients with familial adenomatous polyposis

          -  History of other diarrheal illnesses: lactose intolerance, celiac disease, small bowel
             bacterial overgrowth

          -  Primary Sclerosing Cholangitis with or without liver transplant

          -  Uncontrolled systemic disease

          -  Needing oral or topical 5-ASA, cholestyramine, steroids or immunomodulators

          -  Other major physical or major psychiatric illness within the last 6 months that in the
             opinion of the investigator would affect the patient's ability to complete the trial

          -  Women who are pregnant, breast feeding, or planning to become pregnant during the
             study

          -  Women of child-bearing potential who are not willing to use barrier or depot
             contraception methods

          -  Use of NSAIDs or aspirin (&gt;3 times per week) within the past 3 weeks
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Darrell S. Pardi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic College of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic, Inflammatory Bowel Disease Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Sandborn WJ. Pouchitis following ileal pouch-anal anastomosis: definition, pathogenesis, and treatment. Gastroenterology. 1994 Dec;107(6):1856-60. Review.</citation>
    <PMID>7958702</PMID>
  </reference>
  <reference>
    <citation>Fazio VW, Ziv Y, Church JM, Oakley JR, Lavery IC, Milsom JW, Schroeder TK. Ileal pouch-anal anastomoses complications and function in 1005 patients. Ann Surg. 1995 Aug;222(2):120-7.</citation>
    <PMID>7639579</PMID>
  </reference>
  <reference>
    <citation>Simchuk EJ, Thirlby RC. Risk factors and true incidence of pouchitis in patients after ileal pouch-anal anastomoses. World J Surg. 2000 Jul;24(7):851-6.</citation>
    <PMID>10833254</PMID>
  </reference>
  <reference>
    <citation>Salemans JM, Nagengast FM, Lubbers EJ, Kuijpers JH. Postoperative and long-term results of ileal pouch-anal anastomosis for ulcerative colitis and familial polyposis coli. Dig Dis Sci. 1992 Dec;37(12):1882-9.</citation>
    <PMID>1335407</PMID>
  </reference>
  <reference>
    <citation>Marcello PW, Roberts PL, Schoetz DJ Jr, Coller JA, Murray JJ, Veidenheimer MC. Long-term results of the ileoanal pouch procedure. Arch Surg. 1993 May;128(5):500-3; discussion 503-4.</citation>
    <PMID>8489382</PMID>
  </reference>
  <reference>
    <citation>Meagher AP, Farouk R, Dozois RR, Kelly KA, Pemberton JH. J ileal pouch-anal anastomosis for chronic ulcerative colitis: complications and long-term outcome in 1310 patients. Br J Surg. 1998 Jun;85(6):800-3.</citation>
    <PMID>9667712</PMID>
  </reference>
  <reference>
    <citation>Svaninger G, Nordgren S, Oresland T, Hultén L. Incidence and characteristics of pouchitis in the Kock continent ileostomy and the pelvic pouch. Scand J Gastroenterol. 1993 Aug;28(8):695-700.</citation>
    <PMID>8210985</PMID>
  </reference>
  <reference>
    <citation>Shepherd NA, Hultén L, Tytgat GN, Nicholls RJ, Nasmyth DG, Hill MJ, Fernandez F, Gertner DJ, Rampton DS, Hill MJ, et al. Pouchitis. Int J Colorectal Dis. 1989 Dec;4(4):205-29. Review.</citation>
    <PMID>2693561</PMID>
  </reference>
  <reference>
    <citation>Sandborn WJ. Pouchitis: risk factors, frequency, natural history, classification and public health perspective. Kluwer Academic Publishers, 1997.</citation>
  </reference>
  <reference>
    <citation>Sandborn WJ, Pardi DS. Clinical management of pouchitis. Gastroenterology. 2004 Dec;127(6):1809-14.</citation>
    <PMID>15578518</PMID>
  </reference>
  <reference>
    <citation>Sagar PM, Pemberton JH. Ileo-anal pouch function and dysfunction. Dig Dis. 1997 May-Jun;15(3):172-88. Review.</citation>
    <PMID>9158926</PMID>
  </reference>
  <reference>
    <citation>Lohmuller JL, Pemberton JH, Dozois RR, Ilstrup D, van Heerden J. Pouchitis and extraintestinal manifestations of inflammatory bowel disease after ileal pouch-anal anastomosis. Ann Surg. 1990 May;211(5):622-7; discussion 627-9.</citation>
    <PMID>2339922</PMID>
  </reference>
  <reference>
    <citation>Tytgat GN, van Deventer SJ. Pouchitis. Int J Colorectal Dis. 1988 Nov;3(4):226-8. Review.</citation>
    <PMID>3058838</PMID>
  </reference>
  <reference>
    <citation>Shen B, Achkar JP, Lashner BA, Ormsby AH, Remzi FH, Bevins CL, Brzezinski A, Petras RE, Fazio VW. Endoscopic and histologic evaluation together with symptom assessment are required to diagnose pouchitis. Gastroenterology. 2001 Aug;121(2):261-7.</citation>
    <PMID>11487535</PMID>
  </reference>
  <reference>
    <citation>Hurst RD, Molinari M, Chung TP, Rubin M, Michelassi F. Prospective study of the incidence, timing and treatment of pouchitis in 104 consecutive patients after restorative proctocolectomy. Arch Surg. 1996 May;131(5):497-500; discussion 501-2.</citation>
    <PMID>8624195</PMID>
  </reference>
  <reference>
    <citation>Duffy M, O'Mahony L, Coffey JC, Collins JK, Shanahan F, Redmond HP, Kirwan WO. Sulfate-reducing bacteria colonize pouches formed for ulcerative colitis but not for familial adenomatous polyposis. Dis Colon Rectum. 2002 Mar;45(3):384-8.</citation>
    <PMID>12068199</PMID>
  </reference>
  <reference>
    <citation>Gosselink MP, Schouten WR, van Lieshout LM, Hop WC, Laman JD, Ruseler-van Embden JG. Eradication of pathogenic bacteria and restoration of normal pouch flora: comparison of metronidazole and ciprofloxacin in the treatment of pouchitis. Dis Colon Rectum. 2004 Sep;47(9):1519-25. Epub 2004 Jul 8.</citation>
    <PMID>15486751</PMID>
  </reference>
  <reference>
    <citation>Gionchetti P, Rizzello F, Venturi A, Ugolini F, Rossi M, Brigidi P, Johansson R, Ferrieri A, Poggioli G, Campieri M. Antibiotic combination therapy in patients with chronic, treatment-resistant pouchitis. Aliment Pharmacol Ther. 1999 Jun;13(6):713-8.</citation>
    <PMID>10383499</PMID>
  </reference>
  <reference>
    <citation>Kmiot WA, Youngs D, Tudor R, Thompson H, Keighley MR. Mucosal morphology, cell proliferation and faecal bacteriology in acute pouchitis. Br J Surg. 1993 Nov;80(11):1445-9.</citation>
    <PMID>8252361</PMID>
  </reference>
  <reference>
    <citation>Nasmyth DG, Godwin PG, Dixon MF, Williams NS, Johnston D. Ileal ecology after pouch-anal anastomosis or ileostomy. A study of mucosal morphology, fecal bacteriology, fecal volatile fatty acids, and their interrelationship. Gastroenterology. 1989 Mar;96(3):817-24.</citation>
    <PMID>2914643</PMID>
  </reference>
  <reference>
    <citation>Schmidt CM, Lazenby AJ, Hendrickson RJ, Sitzmann JV. Preoperative terminal ileal and colonic resection histopathology predicts risk of pouchitis in patients after ileoanal pull-through procedure. Ann Surg. 1998 May;227(5):654-62; discussion 663-5.</citation>
    <PMID>9605657</PMID>
  </reference>
  <reference>
    <citation>Ståhlberg D, Gullberg K, Liljeqvist L, Hellers G, Löfberg R. Pouchitis following pelvic pouch operation for ulcerative colitis. Incidence, cumulative risk, and risk factors. Dis Colon Rectum. 1996 Sep;39(9):1012-8.</citation>
    <PMID>8797652</PMID>
  </reference>
  <reference>
    <citation>Hata K, Watanabe T, Shinozaki M, Nagawa H. Patients with extraintestinal manifestations have a higher risk of developing pouchitis in ulcerative colitis: multivariate analysis. Scand J Gastroenterol. 2003 Oct;38(10):1055-8.</citation>
    <PMID>14621280</PMID>
  </reference>
  <reference>
    <citation>Penna C, Dozois R, Tremaine W, Sandborn W, LaRusso N, Schleck C, Ilstrup D. Pouchitis after ileal pouch-anal anastomosis for ulcerative colitis occurs with increased frequency in patients with associated primary sclerosing cholangitis. Gut. 1996 Feb;38(2):234-9.</citation>
    <PMID>8801203</PMID>
  </reference>
  <reference>
    <citation>Achkar JP, Al-Haddad M, Lashner B, Remzi FH, Brzezinski A, Shen B, Khandwala F, Fazio V. Differentiating risk factors for acute and chronic pouchitis. Clin Gastroenterol Hepatol. 2005 Jan;3(1):60-6.</citation>
    <PMID>15645406</PMID>
  </reference>
  <reference>
    <citation>Shen B, Fazio VW, Remzi FH, Delaney CP, Bennett AE, Achkar JP, Brzezinski A, Khandwala F, Liu W, Bambrick ML, Bast J, Lashner B. Comprehensive evaluation of inflammatory and noninflammatory sequelae of ileal pouch-anal anastomoses. Am J Gastroenterol. 2005 Jan;100(1):93-101.</citation>
    <PMID>15654787</PMID>
  </reference>
  <reference>
    <citation>Sandborn WJ, Landers CJ, Tremaine WJ, Targan SR. Antineutrophil cytoplasmic antibody correlates with chronic pouchitis after ileal pouch-anal anastomosis. Am J Gastroenterol. 1995 May;90(5):740-7.</citation>
    <PMID>7733080</PMID>
  </reference>
  <reference>
    <citation>Aisenberg J, Legnani PE, Nilubol N, Cobrin GM, Ellozy SH, Hegazi RA, Yager J, Bodian C, Gorfine SR, Bauer JJ, Plevy SE, Sachar DB. Are pANCA, ASCA, or cytokine gene polymorphisms associated with pouchitis? Long-term follow-up in 102 ulcerative colitis patients. Am J Gastroenterol. 2004 Mar;99(3):432-41.</citation>
    <PMID>15056081</PMID>
  </reference>
  <reference>
    <citation>Merrett MN, Mortensen N, Kettlewell M, Jewell DO. Smoking may prevent pouchitis in patients with restorative proctocolectomy for ulcerative colitis. Gut. 1996 Mar;38(3):362-4.</citation>
    <PMID>8675087</PMID>
  </reference>
  <reference>
    <citation>Di Febo G, Miglioli M, Lauri A, Biasco G, Paganelli GM, Poggioli G, Gozzetti G, Barbara L. Endoscopic assessment of acute inflammation of the ileal reservoir after restorative ileo-anal anastomosis. Gastrointest Endosc. 1990 Jan-Feb;36(1):6-9.</citation>
    <PMID>2155847</PMID>
  </reference>
  <reference>
    <citation>Moskowitz RL, Shepherd NA, Nicholls RJ. An assessment of inflammation in the reservoir after restorative proctocolectomy with ileoanal ileal reservoir. Int J Colorectal Dis. 1986 Jul;1(3):167-74.</citation>
    <PMID>3039030</PMID>
  </reference>
  <reference>
    <citation>Shen B, Shermock KM, Fazio VW, Achkar JP, Brzezinski A, Bevins CL, Bambrick ML, Remzi FH, Lashner BA. A cost-effectiveness analysis of diagnostic strategies for symptomatic patients with ileal pouch-anal anastomosis. Am J Gastroenterol. 2003 Nov;98(11):2460-7.</citation>
    <PMID>14638349</PMID>
  </reference>
  <reference>
    <citation>Shepherd NA, Jass JR, Duval I, Moskowitz RL, Nicholls RJ, Morson BC. Restorative proctocolectomy with ileal reservoir: pathological and histochemical study of mucosal biopsy specimens. J Clin Pathol. 1987 Jun;40(6):601-7.</citation>
    <PMID>3611389</PMID>
  </reference>
  <reference>
    <citation>Parsi MA, Shen B, Achkar JP, Remzi FF, Goldblum JR, Boone J, Lin D, Connor JT, Fazio VW, Lashner BA. Fecal lactoferrin for diagnosis of symptomatic patients with ileal pouch-anal anastomosis. Gastroenterology. 2004 May;126(5):1280-6.</citation>
    <PMID>15131788</PMID>
  </reference>
  <reference>
    <citation>Johnson MW, Dewar DH, Ciclitira P, Forbes A, Nicholls RJ, Bjarnason I. Use of fecal lactoferrin to diagnose irritable pouch syndrome: a word of caution. Gastroenterology. 2004 Nov;127(5):1647-8; author reply 1648.</citation>
    <PMID>15521043</PMID>
  </reference>
  <reference>
    <citation>Mann SD, Pitt J, Springall RG, Thillainayagam AV. Clostridium difficile infection--an unusual cause of refractory pouchitis: report of a case. Dis Colon Rectum. 2003 Feb;46(2):267-70. Review.</citation>
    <PMID>12576902</PMID>
  </reference>
  <reference>
    <citation>Seggerman RE, Chen MY, Waters GS, Ott DJ. Pictorial essay. Radiology of ileal pouch-anal anastomosis surgery. AJR Am J Roentgenol. 2003 Apr;180(4):999-1002.</citation>
    <PMID>12646444</PMID>
  </reference>
  <reference>
    <citation>Libicher M, Scharf J, Wunsch A, Stern J, Düx M, Kauffmann GW. MRI of pouch-related fistulas in ulcerative colitis after restorative proctocolectomy. J Comput Assist Tomogr. 1998 Jul-Aug;22(4):664-8.</citation>
    <PMID>9676464</PMID>
  </reference>
  <reference>
    <citation>Shen B, Lashner BA, Bennett AE, Remzi FH, Brzezinski A, Achkar JP, Bast J, Bambrick ML, Fazio VW. Treatment of rectal cuff inflammation (cuffitis) in patients with ulcerative colitis following restorative proctocolectomy and ileal pouch-anal anastomosis. Am J Gastroenterol. 2004 Aug;99(8):1527-31.</citation>
    <PMID>15307872</PMID>
  </reference>
  <reference>
    <citation>Thompson-Fawcett MW, Mortensen NJ, Warren BF. &quot;Cuffitis&quot; and inflammatory changes in the columnar cuff, anal transitional zone, and ileal reservoir after stapled pouch-anal anastomosis. Dis Colon Rectum. 1999 Mar;42(3):348-55.</citation>
    <PMID>10223755</PMID>
  </reference>
  <reference>
    <citation>Keighley MR. Review article: the management of pouchitis. Aliment Pharmacol Ther. 1996 Aug;10(4):449-57. Review.</citation>
    <PMID>8853749</PMID>
  </reference>
  <reference>
    <citation>Muñoz-Juarez M, Pemberton JH, Sandborn WJ, Tremaine WJ, Dozois RR. Misdiagnosis of specific cytomegalovirus infection of the ileoanal pouch as refractory idiopathic chronic pouchitis: report of two cases. Dis Colon Rectum. 1999 Jan;42(1):117-20.</citation>
    <PMID>10211531</PMID>
  </reference>
  <reference>
    <citation>Moonka D, Furth EE, MacDermott RP, Lichtenstein GR. Pouchitis associated with primary cytomegalovirus infection. Am J Gastroenterol. 1998 Feb;93(2):264-6.</citation>
    <PMID>9468256</PMID>
  </reference>
  <reference>
    <citation>Salfiti N, Loftus EV, Tremaine WJ, Pardi DS, et al. Clinical features and outcomes of cytomegalovirus colitis or pouchitis in patients with inflammatory bowel disease. Am J Gastroenterol 100:S316, 2005</citation>
  </reference>
  <reference>
    <citation>Shen B, Achkar JP, Lashner BA, Ormsby AH, Brzezinski A, Soffer EE, Remzi FH, Bevins CL, Fazio VW. Irritable pouch syndrome: a new category of diagnosis for symptomatic patients with ileal pouch-anal anastomosis. Am J Gastroenterol. 2002 Apr;97(4):972-7.</citation>
    <PMID>12003434</PMID>
  </reference>
  <reference>
    <citation>Prudhomme M, Dozois RR, Godlewski G, Mathison S, Fabbro-Peray P. Anal canal strictures after ileal pouch-anal anastomosis. Dis Colon Rectum. 2003 Jan;46(1):20-3.</citation>
    <PMID>12544517</PMID>
  </reference>
  <reference>
    <citation>Madden MV, McIntyre AS, Nicholls RJ. Double-blind crossover trial of metronidazole versus placebo in chronic unremitting pouchitis. Dig Dis Sci. 1994 Jun;39(6):1193-6.</citation>
    <PMID>8200250</PMID>
  </reference>
  <reference>
    <citation>Shen B, Achkar JP, Lashner BA, Ormsby AH, Remzi FH, Brzezinski A, Bevins CL, Bambrick ML, Seidner DL, Fazio VW. A randomized clinical trial of ciprofloxacin and metronidazole to treat acute pouchitis. Inflamm Bowel Dis. 2001 Nov;7(4):301-5.</citation>
    <PMID>11720319</PMID>
  </reference>
  <reference>
    <citation>Sambuelli A, Boerr L, Negreira S, Gil A, Camartino G, Huernos S, Kogan Z, Cabanne A, Graziano A, Peredo H, Doldán I, Gonzalez O, Sugai E, Lumi M, Bai JC. Budesonide enema in pouchitis--a double-blind, double-dummy, controlled trial. Aliment Pharmacol Ther. 2002 Jan;16(1):27-34.</citation>
    <PMID>11856075</PMID>
  </reference>
  <reference>
    <citation>Mimura T, Rizzello F, Helwig U, Poggioli G, Schreiber S, Talbot IC, Nicholls RJ, Gionchetti P, Campieri M, Kamm MA. Four-week open-label trial of metronidazole and ciprofloxacin for the treatment of recurrent or refractory pouchitis. Aliment Pharmacol Ther. 2002 May;16(5):909-17.</citation>
    <PMID>11966499</PMID>
  </reference>
  <reference>
    <citation>Nygaard K, Bergan T, Bjørneklett A, Høverstad T, Lassen J, Aase S. Topical metronidazole treatment in pouchitis. Scand J Gastroenterol. 1994 May;29(5):462-7.</citation>
    <PMID>8036463</PMID>
  </reference>
  <reference>
    <citation>Gionchetti P, Rizzello F, Venturi A, Brigidi P, Matteuzzi D, Bazzocchi G, Poggioli G, Miglioli M, Campieri M. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology. 2000 Aug;119(2):305-9.</citation>
    <PMID>10930365</PMID>
  </reference>
  <reference>
    <citation>Mimura T, Rizzello F, Helwig U, Poggioli G, Schreiber S, Talbot IC, Nicholls RJ, Gionchetti P, Campieri M, Kamm MA. Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut. 2004 Jan;53(1):108-14.</citation>
    <PMID>14684584</PMID>
  </reference>
  <reference>
    <citation>Gionchetti P, Rizzello F, Helwig U, Venturi A, Lammers KM, Brigidi P, Vitali B, Poggioli G, Miglioli M, Campieri M. Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology. 2003 May;124(5):1202-9.</citation>
    <PMID>12730861</PMID>
  </reference>
  <reference>
    <citation>Shen B, Brzezinski A, Fazio VW, Remzi FH, Achkar JP, Bennett AE, Sherman K, Lashner BA. Maintenance therapy with a probiotic in antibiotic-dependent pouchitis: experience in clinical practice. Aliment Pharmacol Ther. 2005 Oct 15;22(8):721-8.</citation>
    <PMID>16197493</PMID>
  </reference>
  <reference>
    <citation>Chopra A, Pardi DS, Loftus EV Jr, Tremaine WJ, Egan LJ, Faubion WA, Hanson KA, Johnson TA, Sandborn WJ. Budesonide in the treatment of inflammatory bowel disease: the first year of experience in clinical practice. Inflamm Bowel Dis. 2006 Jan;12(1):29-32.</citation>
    <PMID>16374255</PMID>
  </reference>
  <reference>
    <citation>Gionchetti P, Rizzello F, Morselli C, et al. Eight-week trial of oral budesonide for the treatment of refractory pouchitis. Gastroenterology 126:A123, 2004</citation>
  </reference>
  <reference>
    <citation>Miglioli M, Barbara L, Di Febo G, Gozzetti G, Lauri A, Paganelli GM, Poggioli G, Santucci R. Topical administration of 5-aminosalicylic acid: a therapeutic proposal for the treatment of pouchitis. N Engl J Med. 1989 Jan 26;320(4):257.</citation>
    <PMID>2911318</PMID>
  </reference>
  <reference>
    <citation>Viscido A, Habib FI, Kohn A, Papi C, Marcheggiano A, Pimpo MT, Vernia P, Cadau G, Caprilli R. Infliximab in refractory pouchitis complicated by fistulae following ileo-anal pouch for ulcerative colitis. Aliment Pharmacol Ther. 2003 May 15;17(10):1263-71.</citation>
    <PMID>12755839</PMID>
  </reference>
  <reference>
    <citation>Gionchetti P, Rizzello F, Venturi A, Ferretti M, Brignola C, Peruzzo S, Belloli C, Poggioli G, Miglioli M, Campieri M. Long-term efficacy of bismuth carbomer enemas in patients with treatment-resistant chronic pouchitis. Aliment Pharmacol Ther. 1997 Aug;11(4):673-8.</citation>
    <PMID>9305474</PMID>
  </reference>
  <reference>
    <citation>Tremaine WJ, Sandborn WJ, Kenan ML. Bismuth subsalicylate tablets for chronic antibiotic-resistant pouchitis. Gastroenterology 114:A1101, 1998.</citation>
  </reference>
  <reference>
    <citation>Wischmeyer P, Pemberton JH, Phillips SF. Chronic pouchitis after ileal pouch-anal anastomosis: responses to butyrate and glutamine suppositories in a pilot study. Mayo Clin Proc. 1993 Oct;68(10):978-81.</citation>
    <PMID>8412364</PMID>
  </reference>
  <reference>
    <citation>Tremaine WJ, Sandborn WJ, Wolff BG, Carpenter HA, Zinsmeister AR, Metzger PP. Bismuth carbomer foam enemas for active chronic pouchitis: a randomized, double-blind, placebo-controlled trial. Aliment Pharmacol Ther. 1997 Dec;11(6):1041-6.</citation>
    <PMID>9663827</PMID>
  </reference>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 20, 2007</study_first_submitted>
  <study_first_submitted_qc>December 20, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 31, 2007</study_first_posted>
  <disposition_first_submitted>July 26, 2013</disposition_first_submitted>
  <disposition_first_submitted_qc>June 2, 2014</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">June 18, 2014</disposition_first_posted>
  <last_update_submitted>June 2, 2014</last_update_submitted>
  <last_update_submitted_qc>June 2, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 18, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Antibiotic-refractory Pouchitis</keyword>
  <keyword>Pouchitis</keyword>
  <keyword>Ulcerative Colitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pouchitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Antibiotics, Antitubercular</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

